-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Japan's Ministry of Health, Labor and Welfare urgently approved a Japanese-made new crown oral drug on the 22nd, which is the first drug
approved after Japan established a relevant emergency approval system in May this year.
approved after Japan established a relevant emergency approval system in May this year.
The tablet called XOCOVA developed by Shionogi Pharmaceutical Company of Japan was approved on the same day, and its active ingredient was ensetivir fumarate
.
According to the press release released by the Ministry of Health, Labor and Welfare on the same day, this drug was approved for use in people over 12 years old with new crown infection, once a day for 5 days
.
.
According to the press release released by the Ministry of Health, Labor and Welfare on the same day, this drug was approved for use in people over 12 years old with new crown infection, once a day for 5 days
.
The communiqué said the drug inhibited viral replication
by affecting the 3CL protease of the new coronavirus.
In clinical trials, it can effectively shorten the time required for symptoms such as fatigue, fever, nasal discharge or nasal congestion, sore throat, and cough in people infected with the new
crown to disappear.
by affecting the 3CL protease of the new coronavirus.
In clinical trials, it can effectively shorten the time required for symptoms such as fatigue, fever, nasal discharge or nasal congestion, sore throat, and cough in people infected with the new
crown to disappear.
Japan's previously approved new crown oral drugs include the Pfizer nematevir/ritonavir combination (Paxlovid) and Merck's monabigravir
.
However, these two drugs are only allowed to be used in groups at high risk of severe disease such as elderly new crown patients, and XOCOVA has no similar restrictions and has received widespread attention
.
.
However, these two drugs are only allowed to be used in groups at high risk of severe disease such as elderly new crown patients, and XOCOVA has no similar restrictions and has received widespread attention
.
According to the relevant emergency approval system established in Japan in May this year, after the emergency approval of a drug, its manufacturer and seller must continue clinical trials to further confirm the effectiveness and safety of the drug, and apply for approval
again within two years.
If efficacy and safety are not confirmed, approval may be revoked
.
again within two years.
If efficacy and safety are not confirmed, approval may be revoked
.
